Portuguese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Clinical Drug Investigation 2002-Sep

RETRACTED ARTICLE: Combination Antiemetic Regimens for Prevention of Postoperative Nausea and Vomiting : Focus on High-Risk Patients.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
O link é salvo na área de transferência
Yoshitaka Fujii

Palavras-chave

Resumo

None of the available antiemetics is entirely effective, perhaps because most of them act through the blockade of one receptor. There is a possibility that a combination of antiemetics with different sites of activity would be more effective than one drug alone for prophylaxis against postoperative nausea and vomiting (PONV).The clinical use of combined traditional antiemetics, including antihistamines (e.g. diphenhydramine), butyrophenones (e.g. droperidol) and benzamides (e.g. metoclopramide), for the prevention of PONV is limited because of the possibility of additive central nervous system toxicity, such as delayed emergence, drowsiness and extrapyramidal reactions. The efficacy of a combination of a serotonin 5-HT3 receptor antagonist (ondansetron, granisetron or tropisetron) and dexamethasone is superior to that of 5-HT3 receptor antagonists alone for the prevention of PONV, suggesting that dexamethasone enhances the antiemetic efficacy of 5-HT3 receptor antagonists. The combination of a 5-HT3 receptor antagonist with a traditional antiemetic (droperidol, metoclopramide or promethazine) acting at a different emetogenic receptor is more effective in reducing the incidence of PONV than each antiemetic alone acting at one receptor site. The risk of undesirable adverse effects does not increase with the combination of a 5-HT3 receptor antagonist and a traditional antiemetic at the doses commonly used for PONV, because of the absence of drug interactions. The combination of a 5-HT3 receptor antagonist (ondansetron) with other agents (propofol and CP-122721) reduces the incidence of PONV to a greater degree than monotherapy. However, no data are available for the combination of 5-HT3 receptor antagonists and small doses of propofol for the prevention of PONV.Further studies are needed to evaluate the efficacy and safety of combination antiemetic regimens for PONV. Knowledge regarding combinations of these antiemetic drugs may be necessary to completely prevent PONV.

Junte-se à nossa
página do facebook

O mais completo banco de dados de ervas medicinais apoiado pela ciência

  • Funciona em 55 idiomas
  • Curas herbais apoiadas pela ciência
  • Reconhecimento de ervas por imagem
  • Mapa GPS interativo - marcar ervas no local (em breve)
  • Leia publicações científicas relacionadas à sua pesquisa
  • Pesquise ervas medicinais por seus efeitos
  • Organize seus interesses e mantenha-se atualizado com as notícias de pesquisa, testes clínicos e patentes

Digite um sintoma ou doença e leia sobre ervas que podem ajudar, digite uma erva e veja as doenças e sintomas contra os quais ela é usada.
* Todas as informações são baseadas em pesquisas científicas publicadas

Google Play badgeApp Store badge